Evidence map›Paper›PMID 42398671›Full record

ArticleClinical medicine (London, England)2026

Finerenone exposure and ischaemic stroke in patients with type 2 diabetes and chronic kidney disease: A propensity score-matched cohort study.

Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wu-Lung ChuangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, Lukang Christian Hospital, Changhua 505, Taiwan. Electronic address: wl.chuang@cch.org.tw.
Ruey-Hwang ChouGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan; Department of Medical Laboratory and Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address: rhchou@mail.cmu.edu.tw.
Yuan-Hung WangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan. Electronic address: d508091002@tmu.edu.tw.
I-Ju TsaiManagement Office for Health Data, China Medical University Hospital, Taichung 404, Taiwan. Electronic address: milly1982@ntuh.gov.tw.
Cheng-Li LinManagement Office for Health Data, China Medical University Hospital, Taichung 404, Taiwan; College of Medicine, China Medical University, Taichung 404, Taiwan. Electronic address: 021467@tool.caaumed.org.tw.
Der-Yang ChoTranslational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan; Department of Neurosurgery, China Medical University Hospital, Taichung 40447, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40447, Taiwan. Electronic address: dycho@tool.caaumed.org.tw.
Kuang-Hsi ChangDepartment of Long-Term Care, College of Nursing, Asia University, Taichung 413, Taiwan. Electronic address: khchang@asia.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) commonly coexist and are associated with an increased risk of ischaemic stroke. Finerenone has demonstrated benefits on composite renal and cardiovascular outcomes in randomised trials; however, ischaemic stroke has generally been evaluated as part of composite endpoints, and real-world evidence focusing on this outcome remains limited.

methodsWe conducted a retrospective cohort study using the TriNetX Global Research Network to evaluate the association between finerenone use and incident ischaemic stroke among adults with newly diagnosed T2DM who subsequently developed CKD. Finerenone users were compared with non-users. Propensity score matching was applied to balance demographic characteristics and baseline comorbidities. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs).

resultsA total of 125,086 eligible patients were identified before matching, including 1,990 finerenone users. After 1:1 propensity score matching, 1,990 finerenone users were matched with 1,990 non-users with adequate covariate balance. Finerenone use was associated with a lower observed hazard of ischaemic stroke both before matching (adjusted HR, 0.30; 95% CI, 0.24-0.36) and after matching (adjusted HR, 0.33; 95% CI, 0.26-0.42).

conclusionsIn this real-world cohort of patients with T2DM and CKD, finerenone use was associated with a lower observed hazard of ischaemic stroke.

Indexed as

Chronic kidney diseaseFinerenoneIschaemic strokeReal-world evidenceType 2 diabetes mellitus

Identifiers

PMID42398671
PMCPMC13475410

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.